Clinical trial • Phase I • Immunology

PIT565 for Systemic lupus erythematosus

Phase I trial of PIT565 for Systemic lupus erythematosus. open-label, none/not specified-controlled, adaptive. 12 participants.

Overview

Trial Therapeutic Area
Immunology
Trial Disease
Systemic lupus erythematosus
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
17-05-2024
First CTIS Authorization Date
09-09-2024

Trial design

open-label, none/not specified-controlled, adaptive Phase I trial across 10 sites in Bulgaria, Germany, Spain and others.

Open Label
Yes
Comparator
None/Not specified
Adaptive
True, ascending dose (dose-escalation) study with step-up doses to assess safety, tolerability and pharmacokinetics; detailed escalation rules, interim analyses, and stopping rules not provided in the CTIS record.
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
12

Eligibility

Recruits 12 Vulnerable population selected; no details on consent or assent handling provided in the CTIS record..

Vulnerable Population
Vulnerable population selected; no details on consent or assent handling provided in the CTIS record.

Recruitment

Planned Sample Size
12
Recruitment Window Months
32

Geography

Total Number Of Sites
10
Total Number Of Participants
32

Bulgaria

Earliest CTIS Part Ii Submission Date
12-08-2024
Latest Decision Or Authorization Date
16-09-2024
Processing Time Days
35
Number Of Sites
1
Number Of Participants
3

Sites

Site Name
Medical Center Comac Medical Ltd.
Department Name
#1004
Contact Person Name
Rumen Stoilov
Contact Person Email
rmstoilov@abv.bg

Germany

Earliest CTIS Part Ii Submission Date
12-08-2024
Latest Decision Or Authorization Date
12-09-2024
Processing Time Days
31
Number Of Sites
3
Number Of Participants
16

Sites

Site Name
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Department Name
1002: I. Medizinische Klinik und Poliklinik
Contact Person Name
Julia Weinmann-Menke
Site Name
Universitaetsklinikum Essen AöR
Department Name
1014:Klinik für Nephrologie und Infektiologie
Contact Person Name
Sebastian Dolff
Contact Person Email
Sebastian.dolff@uk-essen.de
Site Name
Charite Research Organisation GmbH
Department Name
1001
Contact Person Name
Stanislav Ignatenko

Spain

Earliest CTIS Part Ii Submission Date
28-03-2024
Latest Decision Or Authorization Date
19-09-2024
Processing Time Days
175
Number Of Sites
3
Number Of Participants
5

Sites

Site Name
Complexo Hospitalario Universitario De Santiago
Department Name
#1006: Rheumatology
Contact Person Name
Eva Maria Perez Pampin
Contact Person Email
eva.perez.pampin@sergas.es
Site Name
Hospital Universitario Ramon Y Cajal
Department Name
#1013; Rheumatology
Contact Person Name
Maria Jesus Garcia Villanueva
Contact Person Email
machusgv@gmail.com
Site Name
Hospital Universitari Vall D Hebron
Department Name
#1005: Rheumatology
Contact Person Name
Josefina Cortes Hernandez
Contact Person Email
fina.cortes@vhir.org

Netherlands

Earliest CTIS Part Ii Submission Date
30-08-2024
Latest Decision Or Authorization Date
12-09-2024
Processing Time Days
13
Number Of Sites
1
Number Of Participants
4

Sites

Site Name
Centre for Human Drug Research
Department Name
#1003: Internal Medicine
Contact Person Name
Naomi Klarenbeek
Contact Person Email
nklarenbeek@chdr.nl

Hungary

Earliest CTIS Part Ii Submission Date
14-07-2025
Latest Decision Or Authorization Date
22-08-2025
Processing Time Days
39
Number Of Sites
2
Number Of Participants
4

Sites

Site Name
Semmelweis University
Department Name
1011: Belgyógyászati és Onkológiai Klinika, Klinikai Farmakológiai részleg
Contact Person Name
István Takács
Contact Person Email
takacs.istvan@semmelweis.hu
Site Name
University Of Szeged
Department Name
1010: Szent-Györgyi Albert Klinikai Központ, Klinikai Farmakológiai Központ, Fázis I. vizsgálóhely
Principal Investigator Name
Róbert Takács
Contact Person Name
Róbert Takács
Contact Person Email
takacs.robert@med.u-szeged.hu

Sponsor

Primary sponsor

Full Name
Novartis Pharma AG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Switzerland

Investigational products

Investigational Product Name
PIT565

Related trials

Other published trials that may interest you.